# US 8,541,394 B2 · Aminoglycoside antibiotics

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 8,541,394 B2
- Document ID: US8541394B2
- Status: Granted
- Kind: B2
- Application number: 13/413,979
- Filed: 2012-03-07
- Published: 2012-06-28
- Granted: 2013-09-24
- Earliest claimed: 2006-06-02
- Assignees: Meiji Seika Pharma Co., Ltd.; Microbial Chemistry Research Foundation
- Applicants: Yoshihiko Kobayashi; Yoshihisa Akiyama; Takeshi Murakami; Nobuto Minowa; Masaki Tsushima; Yukiko Hiraiwa; Shoichi Murakami; Mitsuhiro Abe; Kazushige Sasaki; Shigeru Hoshiko; Toshiaki Miyake; Yoshiaki Takahashi; Daishiro Ikeda
- Inventors: Yoshihiko Kobayashi; Yoshihisa Akiyama; Takeshi Murakami; Nobuto Minowa; Masaki Tsushima; Yukiko Hiraiwa; Shoichi Murakami; Mitsuhiro Abe; Kazushige Sasaki; Shigeru Hoshiko; Toshiaki Miyake; Yoshiaki Takahashi; Daishiro Ikeda
- Web page: https://patentgrep.com/patent/US8541394B2

## CPC

- C07H 15/234: attached to non-adjacent ring carbon atoms of the cyclohexane rings, e.g. kanamycins, tobramycin, nebramycin, gentamicin A2
- A61P 31/04: Antibacterial agents
- C07H 15/224: with only one saccharide radical directly attached to the cyclohexyl radical, e.g. destomycin, fortimicin, neamine
- C07H: SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS (derivatives of aldonic or saccharic acids C07C, C07D; aldonic acids, saccharic acids C07C59/105, C07C59/285; cyanohydrins C07C255/16; glycals C07D; compounds of unknown constitution C07G; polysaccharides, derivatives thereof C08B; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification C12N15/00; sugar industry C13)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

This invention relates to novel aminoglycoside antibiotics, which have potent antimicrobial activity against bacteria, which induce infectious diseases, particularly MRSA, and has no significant nephrotoxicity, and process for producing them. More particularly, the present invention relates to compounds represented by formula (Ia) or their pharmacologically acceptable salts or solvates, or their diastereomer mixtures, antimicrobial agents comprising them, and a process for producing them.

## Claims

### Claim 1

A method for inhibiting proliferation of methicillin-resistant Staphylococcus aureus, or for sterilizing methicillin-resistant Staphylococcus aureus; comprising administering a compound represented by formula (Ia) or its pharmacologically acceptable salt, or their diastereomer mixture with respect to the carbon atom attached with * to an animal:
wherein
R5ax and R5eq, which are different from each other, represent a hydrogen atom or hydroxyl, and
R4″ax and R4″eq, which are different from each other, represent a hydrogen atom or hydroxyl,
n is an integer of 1 to 4, and
the steric configuration of carbon atom attached with * represents R or S.

### Claim 2 (depends on 1)

The method according to claim 1 or its pharmacologically acceptable salt, or their diastereomer mixture with respect to the carbon atom attached with *, wherein
R5ax represents a hydrogen atom and
R5eq represents hydroxyl.

### Claim 3 (depends on 1)

The method according to claim 1 or its pharmacologically acceptable salt, or their diastereomer mixture with respect to the carbon atom attached with *, wherein
R5ax represents hydroxyl and
R5eq represents a hydrogen atom.

### Claim 4 (depends on 1)

The method according to claim 1, wherein the compound represented by formula (Ia) or its pharmacologically acceptable salt, or their diastereomer mixture with respect to the carbon atom attached with * is a compound represented by formula (I) or its pharmacologically acceptable salt:

### Claim 5 (depends on 1)

The method according to claim 1, wherein the animal is a human.